Jaypee Quino
Research Subjects
Jaypee Quino has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Aritra Sarkar
Pfizer Research and Development
1 shared publication Brent Harrington
Pfizer Research and Development
1 shared publication- Brian Samas
Pharmaceutical Sciences, Pfizer Global R&D, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
1 shared publication - Bruno C. Hancock
Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
1 shared publication Chandler Greenwell
XtalPi Inc, Cambridge, Massachusetts 02142, United States
1 shared publicationDanielle E. Gorka
Pfizer Worldwide R&D, Groton, Connecticut 06340, United States
1 shared publication
Latest Publications
- 24 April 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (6) , 2952-2965
Deconstructing Annealing Phenomena in Modified Release Lipid Multiparticulates
This work investigates annealing-induced changes in modified release lipid multiparticulates composed of glyceryl behenate and poloxamer 407. Multiparticulates were manufactured using multiple lots of excipients and then annealed at 3 different temperatures across 45-50 °C (75% RH) until kinetically stable dissolution profiles were achieved. Throughout annealing, multiparticulates were analyzed using powder X-ray diffraction, scanning electron microscopy, quantitative 1H NMR, Raman spectroscopy, and novel flow-NMR dissolution techniques. Supporting nonlinear mixed effects models helped systematically link these orthogonal tools to dissolution, altogether providing strong evidence of concurrent glyceryl behenate crystal refinement with phase separation and migration of the poloxamer 407 from glyceryl behenate as the drivers for changes in dissolution with annealing. These findings demonstrate the importance of annealing glyceryl behenate-poloxamer 407 multiparticulates to achieve the complex matrix needed for modified release.
- 24 April 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (6) , 2952-2965
Deconstructing Annealing Phenomena in Modified Release Lipid Multiparticulates
This work investigates annealing-induced changes in modified release lipid multiparticulates composed of glyceryl behenate and poloxamer 407. Multiparticulates were manufactured using multiple lots of excipients and then annealed at 3 different temperatures across 45-50 °C (75% RH) until kinetically stable dissolution profiles were achieved. Throughout annealing, multiparticulates were analyzed using powder X-ray diffraction, scanning electron microscopy, quantitative 1H NMR, Raman spectroscopy, and novel flow-NMR dissolution techniques. Supporting nonlinear mixed effects models helped systematically link these orthogonal tools to dissolution, altogether providing strong evidence of concurrent glyceryl behenate crystal refinement with phase separation and migration of the poloxamer 407 from glyceryl behenate as the drivers for changes in dissolution with annealing. These findings demonstrate the importance of annealing glyceryl behenate-poloxamer 407 multiparticulates to achieve the complex matrix needed for modified release.
- 25 July 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (8) , 3800-3814
Tale of Two Polymorphs: Investigating the Structural Differences and Dynamic Relationship between Nirmatrelvir Solid Forms (Paxlovid)
Two anhydrous polymorphs of the novel antiviral medicine nirmatrelvir were discovered during the development of Paxlovid, Pfizer's oral Covid-19 treatment. A comprehensive experimental and computational approach was necessary to distinguish the two closely related polymorphs, herein identified as Forms 1 and 4. This approach paired experimental methods, including powder X-ray diffraction and single-crystal X-ray diffraction, solid-state experimental methods, thermal analysis, solid-state nuclear magnetic resonance and Raman spectroscopy with computational investigations comprising crystal structure prediction, Gibbs free energy calculations, and molecular dynamics simulations of the polymorphic transition. Forms 1 and 4 were ultimately determined to be enantiotropically related polymorphs with Form 1 being the stable form above the transition temperature of similar to 17 degrees C and designated as the nominated form for drug development. The work described in this paper shows the importance of using highly specialized orthogonal approaches to elucidate the subtle differences in structure and properties of similar solid-state forms. This synergistic approach allowed for unprecedented speed in bringing Paxlovid to patients in record time amidst the pandemic.
- 25 July 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (8) , 3800-3814
Tale of Two Polymorphs: Investigating the Structural Differences and Dynamic Relationship between Nirmatrelvir Solid Forms (Paxlovid)
Two anhydrous polymorphs of the novel antiviral medicine nirmatrelvir were discovered during the development of Paxlovid, Pfizer's oral Covid-19 treatment. A comprehensive experimental and computational approach was necessary to distinguish the two closely related polymorphs, herein identified as Forms 1 and 4. This approach paired experimental methods, including powder X-ray diffraction and single-crystal X-ray diffraction, solid-state experimental methods, thermal analysis, solid-state nuclear magnetic resonance and Raman spectroscopy with computational investigations comprising crystal structure prediction, Gibbs free energy calculations, and molecular dynamics simulations of the polymorphic transition. Forms 1 and 4 were ultimately determined to be enantiotropically related polymorphs with Form 1 being the stable form above the transition temperature of similar to 17 degrees C and designated as the nominated form for drug development. The work described in this paper shows the importance of using highly specialized orthogonal approaches to elucidate the subtle differences in structure and properties of similar solid-state forms. This synergistic approach allowed for unprecedented speed in bringing Paxlovid to patients in record time amidst the pandemic.